Baxter commences BAX 855 Phase We trial in hemophilia A Baxter International Inc.

today announced the dosing of the 1st patients in a Stage I medical trial of its business lead investigational candidate, BAX 855, a longer-acting type of a full-size recombinant aspect VIII proteins. BAX 855 is founded on Baxter‘s ADVATE [Antihemophilic Element Plasma/Albumin-Free Technique] full-duration rFVIII molecule and plasma/albumin-free manufacturing procedure. The Stage I trial is usually a potential, open-label study that may assess the protection, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or old with serious hemophilia A.Additional restrictions apply. Individuals interested in learning more about My SPRYCEL Support can contact 1-877-526-7334 or visit A Support Kit will get to the mail, and a SPRYCEL Care Counselor will contact the individual to confirm they have received the package and address queries they may have about SPRYCEL and the program.

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations in Lecada’s open house On Thursday An open house, June 17th, celebrated Lecada Medical Artistry’s grand opening at 3710 West Azeele Street, Tampa. Lecada presents innovative treatments for face and body offering aesthetic and anti-ageing solutions designed to help you appear and feel your very best.